Arrowhead Pharmaceuticals, Inc. Announces Resignation of Marianne De Backer, Director, Effective as of April 2, 2023
February 14, 2023 at 05:18 pm EST
Share
On February 11, 2023, Marianne De Backer, a director of Arrowhead Pharmaceuticals, Inc. (the Company), notified the Company of her decision to resign as a director, effective as of April 2, 2023. Dr. De Backeris an independent director who also serves as a member of the Company's Audit Committee, Compensation Committee, and as Chair of its Nomination Committee. Dr. De Backer's decision to resign was based on her recent appointment as Chief Executive Officer and director of Vir Biotechnology, Inc., and did not result from any disagreement with the Company.
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.